Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Center for Health Care Quality and Outcomes, RTI International, Seattle, Washington, USA.
Alzheimers Dement. 2023 Jan;19(1):150-157. doi: 10.1002/alz.12657. Epub 2022 Mar 16.
We estimate the spending attributable to Alzheimer's disease and related dementias (ADRD) to the United States government for the first 5 years post-diagnosis.
Using data from the Health and Retirement Study matched to Medicare and Medicaid claims, we identify a retrospective cohort of adults with a claims-based ADRD diagnosis along with matched controls.
The costs attributable to ADRD are $15,632 for traditional Medicare and $8833 for Medicaid per dementia case over the first 5 years after diagnosis. Seventy percent of Medicare costs occur in the first 2 years; Medicaid costs are concentrated among the longer-lived beneficiaries who are more likely to need long-term care and become Medicaid eligible.
Because the distribution of the incremental costs varies over time and between insurance programs, when interventions occur and the effect on the disease course will have implications for how much and which program reaps the benefits.
我们估算了美国政府在诊断后 5 年内与阿尔茨海默病及相关痴呆症(ADRD)相关的支出。
我们使用来自健康与退休研究的数据,并与医疗保险和医疗补助索赔相匹配,确定了一个基于索赔的 ADRD 诊断的回顾性成年人队列,以及匹配的对照组。
在诊断后的头 5 年,传统医疗保险中每个痴呆症病例的 ADRD 归因费用为 15632 美元,医疗补助计划为 8833 美元。70%的医疗保险费用发生在最初的 2 年内;医疗补助计划的费用集中在寿命更长的受益人身上,他们更有可能需要长期护理并获得医疗补助资格。
由于增量成本的分布随时间和保险计划而变化,因此干预措施发生的时间以及对疾病进程的影响将对受益程度和受益的计划产生影响。